Evidence map›Paper›PMID 41709208›Full record

ArticleHarm reduction journal2026

Using the HPV vaccine as a public health case study for identifying potential barriers to a Fentanyl vaccine.

Jennifer A Ross, Elissa R Weitzman

Abstract read
In one paragraph

Article in Harm reduction journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jennifer A RossDepartment of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA. Jennifer.Ross@childrens.harvard.edu.
Elissa R WeitzmanDepartment of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.

Funding

NIAID NIH HHS contract 75N93020C00038NIH HEAL contract HHSN272201800047C
6 · The paper itself

Abstract

A fentanyl vaccine would serve as a passive model of overdose prevention and a harm reduction strategy that could save the lives of those at risk of fentanyl overdose. Implementation of this innovation has the potential to be impeded by concerns for safety, efficacy, and risk of unintended harms, as well as resistance to change from clinical, programmatic, and public sectors. The Human Papillomavirus (HPV) vaccine also faced barriers to its implementation, with a lower acceptance rate than other standard vaccines. Concerted efforts to increase uptake of the HPV vaccine have been successful and contributed to the significant declines in HPV infections and associated precancers documented since its introduction. This report summarizes parallels between factors that negatively affected the acceptability of the HPV vaccine which may similarly impact acceptability of a fentanyl vaccine and summarizes potential strategies to mitigate barriers in the potential future implementation of a fentanyl vaccine.

Indexed as

Analgesics, OpioidDrug OverdoseFentanylOpiate OverdoseOpioid-Related DisordersPapillomavirus VaccinesAdolescentFemaleHarm ReductionHumansPapillomavirus InfectionsPatient Acceptance of Health CarePublic HealthAnalgesics, OpioidFentanylPapillomavirus VaccinesAdolescentsBehavioral interventionsFentanylHPVOpioidsOverdosePublic healthVaccine

Identifiers

PMID41709208
PMCPMC13019746

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.